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Richard W. Smalling, MD, PHD
Houston, Texas
Currently accepted standards for gauging quality of care in the treatment of ST-segment elevation
myocardial infarction (STEMI) mainly focus on shortening the time to treatment after the patient ar-
rives at the hospital. But this narrow focus fails to consider the substantial duration of myocardial isch-
emia that exists prior to hospital arrival, and the large number of deaths that occur during the pre-
hospital period. The time from symptom onset until reperfusion occurs is one estimate of total
ischemic time. Several experimental studies and now human clinical studies have conﬁrmed that in-
farct size and mortality are strongly correlated with the total ischemic time, and much less so with its
subintervals like door-to-balloon time. This review will discuss the importance of total ischemic time in
STEMI. (J Am Coll Cardiol Intv 2011;4:599–604) © 2011 by the American College of Cardiology
FoundationMyocardial infarction is the leading cause of
mortality in the United States and the developed
world (1). The current benchmarks for the treat-
ment of ST-segment elevation myocardial in-
farction (STEMI) mainly focus on shortening
the time to treatment after the patient has
arrived at the hospital. This focus fails to con-
sider the large number of deaths with STEMI
that occur before patients even reach the hospi-
tal. There is substantial evidence regarding the
benefits of early reperfusion and the detrimental
effects of late reperfusion in patients with
STEMI (2–5). The information regarding the
need for early intervention for STEMI is not
new and has been discussed at length for
decades.
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In 1977, Reimer et al. (6) described the wave
front phenomenon of myocardial infarction
propagation. In their experiments with circum-
flex artery ligation in dogs, the area of necrosis
was compared with the area at risk when the
artery was occluded for 40 min, 3 h, and 6 h. At
40 min of occlusion, 45% of the myocardium at
risk was irreversibly injured, but fully 55% of the
myocardium at risk was salvageable. However,
by 3 h of occlusion, the salvageable area was
down to 33%, and by 6 h, only 16% remained
salvageable (Fig. 1). Clearly, any benefit of
reperfusion is time-dependent from the first
moment of occlusion.
Mortality With Fibrinolysis
Clinical observations in STEMI patients receiv-
ing fibrinolytic therapy also support the above-
mentioned critical importance of early reperfu-
sion (7,8). The European Myocardial Infarction
Project Group (9) found that there were 15 more
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600lives saved at 30 days per 1,000 patients treated because
of 1-h earlier treatment. In the analysis of Boersma et al.
(10), which included over 50,000 patients from 22
randomized trials, the greatest impact of fibrinolysis was
seen when it was administered within the first 2 h of
symptom onset. In patients presenting within just 1 h of
symptom onset, there were 65 fewer deaths per 1,000
patients treated when compared with patients with longer
duration of symptoms. Both animal and clinical data
support the notion that shortening the duration of infarct
artery occlusions can lead to smaller infarct sizes and
lower mortality. However, this relationship is not linear
and most of the benefit of reperfusion is seen within the
first 2 h of occlusion (Fig. 1). Boersma et al.’s analysis
(10) in humans almost exactly replicates the findings of
Reimer et al. (6) in experimen-
tal animals. These data regard-
ing the relation between time
delay to reperfusion and mor-
tality appear to be extremely
solid.
Mortality With Primary
Percutaneous Coronary
Intervention
The relationship between de-
layed treatment of STEMI and
worsened outcomes is not lim-
ited only to the patients treated
with fibrinolysis (3–5,11). In al-
most 1,800 patients treated with
primary angioplasty, De Luca et
al. (4) described the relationship
between ischemic time and 1-year
mortality. In their study, for every
30-min delay before reperfusion,
the relative mortality risk in-
creased by 7.5%. Cannon et al.
(12), in a 27,000 patient cohort, suggested that the door-to-
balloon time was associated with mortality more than the
symptom-onset-to-balloon time. However, it must be recog-
nized that almost one-half of the patients in this study had very
long door-to-balloon times of 2 h, which would correspond
to prolonged symptom-onset-to-balloon times of 3 to 4 h. The
median door-to-balloon time was 1 h 56 min (symptom-
onset-to-balloon time 3 to 4 h) and the mortality 6.1% fits
nicely on the curve from De Luca et al. (5). It should also be
oted that, in observational studies, patients who died before
eaching the hospital would not be included in analyses of
TEMI intervention outcomes and, thereby, would introduce
survivor bias in studies that were based on patients evaluated
Abbreviations
and Acronyms
CI  confidence interval
FAST-PCI  fibrinolytic
acceleration of ST-segment
elevated myocardial
infarction treatment coupled
with urgent culprit artery
revascularization
MSI  myocardial salvage
index
MVO  microvascular
obstruction
OR  odds ratio
PCI  percutaneous
coronary intervention
PHF  pre-hospital
fibrinolysis
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionnly after hospital arrival (13). aagnetic Resonance Imaging Data for
TEMI and Early Reperfusion
Similar to the observations of Reimer et al. (6) and other
experimental investigations, Tarantini et al. (14) were able
to demonstrate that there was a direct and continuous
relationship between ischemic time, transmural necrosis,
and severe microvascular obstruction (MVO), as assessed by
contrast-enhanced magnetic resonance. In their study of 77
patients with STEMI, for each 30 min of treatment delay,
there was a 37% increase in the risk of transmural necrosis
and a 21% increase in the risk for severe MVO. One other
important finding in this study was that if they were able to
demonstrate the presence of normal blood flow in the
infarct-related artery at the time of percutaneous coronary
intervention (PCI), this was associated with lower rates of
transmural necrosis and severe MVO, suggesting that re-
establishing some coronary flow before reaching the cardiac
catheterization laboratory could be beneficial. These results,
in part, also can explain why the CAPTIM (Comparison of
Angioplasty and Prehospital Thrombolysis in Acute Myo-
cardial Infarction) study patients who presented within the
first 2 h of symptom onset benefited from pre-hospital
fibrinolysis when compared to a transfer-only strategy for
primary PCI (15).
Using magnetic resonance imaging, Francone et al. (16)
reported the impact of PCI delay on myocardial salvage and
infarct size in 70 STEMI patients. They separated the
patients into 4 groups by quartiles of time from symptom
onset to PCI:90 min,90 to 150 min,150 to 360 min,
and 360 min. The mean time in the 90-min group was
1.0  0.1 h. The myocardial salvage percentage was highest
in the 90-min group and declined sharply for the other
groups. This was also true for the extent of MVO. Severe
MVO was detected in 6 of 19 patients treated within 90
min of symptoms, but in 14 of 17 patients treated after 6 h
of symptoms. There were also increases in left ventricular
end-diastolic volume and end-systolic volume in the later
reperfused groups.
Eitel et al. (17) analyzed 208 patients who underwent
PCI for STEMI and calculated a myocardial salvage index
(MSI) described as (area of zone at risk – area of infarct
zone)/(area of zone at risk). The median salvage index in
their study was 48. At 6-month follow-up both the mor-
tality and the cumulative event rates were significantly lower
in patients who had a salvage index higher than the median
MSI of 48. The MSI was highest within the first 2 h of
symptoms. There was a significant inverse correlation of
MSI and duration of symptoms before treatment (r 
0.330, p  0.001) (Fig. 1). In this study, the strongest
redictors of myocardial salvage were complete resolution of
T-segment elevation (beta  0.31, p  0.001), time from
ymptom onset to reperfusion (beta  0.23, p  0.002),
nterior myocardial infarction (beta 0.22, p 0.004), and
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before PCI 2 (beta  0.16, p  0.03). At 6 months, there
ere 10 cardiac deaths in the group with salvage index
elow the median, and only 1 death in the group with
alvage index above the median (mortality 9.6% vs. 1%,
 0.003). The major adverse cardiac events rate at 6
months was also significantly higher in the MSI  median
group (22.1% vs. 2.9%, p  0.001). By contrast, door-to-
balloon time was not a predictor of myocardial salvage in
this study. Ejection fraction and MVO were also not
predictive of 6-month major adverse cardiac events. Thus,
the salvage index was the strongest indicator of major
adverse cardiac events and the time from symptom onset to
reperfusion was one of the strongest predictors of MSI in
this study. To put studies for STEMI outcomes into
perspective, one should take into account that the patients
who have survived the first 3 h of myocardial infarction
would have already had 60% transmural infarction, a 40%
chance of having severe MVO, and would have survived the
highest risk portion of the infarction timeline (14).
Shortening the Time to Treatment
From Symptom Onset
Several important time intervals need to be considered in
Figure 1. Effects of Total Ischemic Time on Infarct Size and Clinical Outco
The experimental animal data, human magnetic resonance imaging data, and
linear ﬁts to the group of data points in the ﬁrst 2 h and a separate ﬁt to the
deﬁnes a cutpoint for optimal outcomes. Figure produced by Ashley Gunter athe treatment of STEMI patients. The first interval is thetime from arterial occlusion to symptoms. There is a certain
period that elapses between the occlusion of the infarct-
related artery and the development of chest pain or similar
symptoms of myocardial infarction (18).
The second interval is the time from the onset of
symptoms to the 911 call. This period depends on the
ability of the patient to realize the seriousness of the
problem and his/her level of awareness. Certainly, we need
to increase the public awareness for the early recognition of
the signs and symptoms of STEMI. We will also need to
discourage the use of personal or family means of transpor-
tation to the emergency department instead of the emer-
gency medical services.
The third interval is the time from the 911 call to the
arrival of medical help. The ultimate duration of this
interval involves the performance of emergency medical
services systems and STEMI systems of care as described by
Ting et al. (19), Nallamothu et al. (20), and Henry et al.
(21). Currently, even in the best centers using standard
order sets, a single phone call system, and a central com-
munication system for rapid transfers and bypassing emer-
gency department evaluation, the in-hospital mortality of
patients with STEMI treated with a primary PCI strategy is
5.7% to 6.6% and the 30-day mortality is around 7% (22).
n lives saved data all fall on essentially the same lines. The dotted lines are
oints beyond 2 h. The intersection at about 120 min of ischemic time
my Yee.mes
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602fibrinolysis in STEMI patients followed immediately by
urgent culprit artery revascularization can decrease both
in-hospital and 30-day mortality and major adverse cardiac
events (23–26). In the series of Danchin et al. (25) in
France, the median time from symptom onset to hospital
admission was 3.6 h for pre-hospital fibrinolysis (PHF),
3.5 h for in-hospital fibrinolysis, 3.2 h for primary percuta-
neous interventions, and 12 h for no reperfusion therapy.
In-hospital mortality was 3.3% for PHF, 8.0% for in-
hospital fibrinolysis, and 6.7% for primary percutaneous
interventions. One-year survival was 94%, 89%, and 89%,
respectively. In a multivariate analysis of predictors of 1-year
survival, PHF was associated with a 0.49 relative risk of
death (95% confidence interval [CI]: 0.24 to 1.00; p 0.05). In
patients with PHF admitted in 3.5 h, in-hospital mortal-
ity was 0% and 1-year survival was 99% (25). In the
FAST-MI (French Registry of Acute ST-Segment Eleva-
tion or Non–ST-Segment Elevation Myocardial Infarction)
study from France in which 18% of the patients had
pre-hospital fibrinolysis, the mortality of patients who had
fibrinolysis followed by immediate PCI was 3.9% (27).
In our area, using the STEMI systems of care and the
implementation of a strategy of fibrinolytic acceleration of
ST-segment elevated myocardial infarction treatment cou-
pled with urgent culprit artery revascularization (FAST-
PCI), we were able to decrease mortality by almost one-half
without paying a penalty in terms of increased bleeding (23).
Our results almost exactly overlap with those of Danchin et
al. (25). Mortality was 3.8% with our FAST-PCI compared
with 6.4% in primary PCI patients. The 30-day relative
mortality risk reduction with FAST-PCI was 0.542
(p  0.0151). The beneficial effect of pre-hospital fibrinolysis
is particularly pronounced when it can be initiated within 2 h
of symptoms as shown by Bonnefoy et al. (15). In their study,
patients randomized to pre-hospital fibrinolysis within 2 h of
symptoms had a 30-day mortality of 2.2% when compared
with 5.7% with primary PCI. Cardiogenic shock was also less
frequent with fibrinolysis than with primary PCI in this group
of patients.
The randomized trials with pre-PCI fibrinolysis to date
have not been properly designed to detect any reduction in
total ischemic time. In the FINESSE (Facilitated Interven-
tion With Enhanced Reperfusion Speed to Stop Events)
trial, the median time to balloon was 2.2 h in all patients
and the symptom onset to first bolus of reteplase was 165
min. Only 60% of the FINESSE patients were treated
within 3 h from the symptom onset and of those who were
treated within 3 h, there was a trend toward more clinical
benefit with reteplase and abciximab combination treatment
(28). None of the patients had pre-hospital fibrinolytic
administration. The FINESSE study showed that the
in-hospital administration of full-dose reteplase with abcix-
imab bolus before urgent PCI in non–low-risk patients with
STEMI did not have an additional benefit over primary dPCI. When the trial data were reanalyzed, the high-risk
patients (TIMI flow grade risk score 3), presenting to a
spoke hospital with symptom onset to balloon time 4 h
fared better with combination-facilitated PCI (hazard ratio:
0.45, p  0.009) (29).
Another large trial for pre-PCI fibrinolysis was the
ASSENT-4 (Assessment of the Safety and Efficacy of a
New Treatment Strategy for Acute Myocardial Infarction)
trial, which has been criticized for: 1) not administering
early antiplatelet therapy; 2) the use of glycoprotein IIb/IIIa
inhibitors was not permitted in the facilitated-PCI group,
except for bailout situations; and 3) the use of clopidogrel
was limited to the stented patients at the time of cardiac
catheterization (30). Although the overall results were
negative for facilitated PCI with full-dose fibrinolysis in the
ASSENT-4 study, patients in that trial who received
fibrinolysis early in the ambulance had better outcomes (30).
hen the data from this trial was reanalyzed and the
atients were restratified according to the time to treatment
nd by enrollment site, patients in the pre-hospital facili-
ated group had the shortest delay in treatment and lowest
ortality (31). In the MITI II (Myocardial Infarction Triage
nd Intervention Project) trial, the patients treated “very
arly” (within 70 min of symptom onset) with pre-hospital
brinolysis had lower mortality (1.2% vs. 8.7%) and smaller
nfarct size (32). In a meta-analysis of pre-hospital fibrino-
ysis, it was shown that the time to reperfusion treatment
as almost an hour shorter with pre-hospital administration
hen compared with the patients with in-hospital treat-
ent, and all-cause mortality was significantly reduced (33).
Four other recent trials have proved the safety and effective-
ess of fibrinolytics followed by urgent PCI. GRACIA 1
Randomized Trial Comparing Stenting Within 24 Hours of
hrombolysis Versus Ischemia-Guided Approach to Throm-
olysed Acute Myocardial Infarction With ST Elevation)
ompared the outcomes with early post-fibrinolysis cardiac
atheterization to a conservative, ischemia-driven catheteriza-
ion strategy (34). At 1 year, patients in the early invasive group
ad fewer primary endpoint events (9% vs. 21%, p  0.0008)
nd a reduced rate of death or reinfarction (7% vs. 12%,
 0.07). There were no differences in major bleeding or
ascular complications.
In TRANSFER-AMI (Trial of Routine Angioplasty and
tenting After Fibrinolysis to Enhance Reperfusion in
cute Myocardial Infarction), all STEMI patients received
brinolytic therapy and were randomized to either standard
reatment or to immediate transfer for PCI within 6 h.
atheterization was performed in 88% of standard treat-
ent patients at a median of 32.5 h after randomization,
nd in 98.5% of the routine early PCI patients at a median
f 2.8 h after randomization. At 30 days, the primary
ndpoint was less frequent in early PCI patients (11.0% vs.
7.2%, p  0.004). Very importantly, there were no
ifferences between the groups in the incidence of major
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603bleeding (35). The CARRESS in AMI (Combined Abcix-
imab Reteplase Stent Study in Acute Myocardial Infarction)
trial (36) used half-dose reteplase and abciximab. Patients
were either immediately transferred for PCI or it was
performed only as clinically indicated for rescue. The
primary outcome was reduced in the immediate-PCI group
(4.4% vs. 10.7, p  0.004). This trial suggested that in a
selected group of patients the combined use of half-dose
reteplase and abciximab followed by transfer for urgent PCI
could be safe and effective. In the NORDISTEMI (Nor-
wegian Study on District Treatment of ST-Elevation Myo-
cardial Infarction) trial (37), the median transfer distance
was 158 km, and the median transfer time was 130 min.
The composite of death, reinfarction, or stroke at 12
months was significantly reduced in the early invasive
fibrinolysis  transfer group compared with the conserva-
ive group (6% vs. 16%, p 0.01). There were no significant
ifferences in the bleeding rates. Borgia et al.’s recent
eta-analysis (34), which included the above-mentioned
rials, showed that the routine early coronary intervention
fter fibrinolysis was associated with a decrease in the
ombined endpoint of death or reinfarction (odds ratio
OR]: 0.65, 95% CI: 0.49 to 0.88; p 0.004) and a decrease
n the recurrent ischemia (OR: 0.25, 95% CI: 0.13 to 0.49;
 0.001). This was achieved without an increase in major
leeding and/or the benefits were maintained at 6 to 12
onths of follow-up. This study is interesting because the
enefit is seen in these post-lytic PCI patients even though the
ytic therapy to PCI time was between 80 and 1,000 min. As
result, we agree withDrs. Henry and Larson that the paradise
s not lost, but rather renamed or redefined (38).
onclusions
STEMI patients with long ischemic times have very little
myocardium left for salvage. Their mortalities are the
highest regardless of the method of reperfusion. Trials that
compared different reperfusion strategies that have similar
ischemic times (generally long) have failed to show any
difference in mortality. As illustrated by Figure 1, experi-
mental animal infarct size, number of lives saved clinically,
and human cardiac magnetic resonance imaging infarct size
data all fall on the same curve with respect to ischemic time.
Quite clearly, ischemic times 120 min provide the most
benefit. Even in Denmark, with short transfer distances,
there was a significant system delay in the treatment of
STEMI patients (39). The patients that were transported
directly to the PCI center had a median delay in
treatment of 172 min and the patients that were trans-
ferred from a local hospital had a median system delay of
240 min. One-half of the patients had a system delay 120
min (28% of the direct transports and 65% of the trans-
ferred) (39). To achieve the goal of total ischemic time
120 min will likely require pre-hospital diagnosis andinitiation of reperfusion immediately at the scene by trained
emergency medical services providers acting under protocol,
coupled with urgent infarct artery PCI after the patient is
transported.
There still has been no randomized trial in the United
States using pre-hospital fibrinolysis and urgent culprit
artery revascularization, compared with primary PCI, to
shorten the total ischemic time. We have placed our faith on
the primary PCI route only, attempting to reduce door-to-
balloon times, and ignoring, for the most part, the pre-
hospital phase of myocardial infarction. The time has come
for us not to ignore the findings of Reimer et al. (6),
Francone et al. (16), Eitel et al. (17), and many others, and
to focus on the total ischemic time rather than focusing on
just one of its components. The goal should be to get rid of
all the unnecessary steps in the care of STEMI patients and
develop the systems of care with the focus of decreasing the
total ischemic time. Therefore, we suggest a randomized
trial designed to cut down the total ischemic time to 120
min, using pre-hospital electrocardiogram followed by acti-
vation of the cardiac catheterization laboratory by the
emergency department physician confirming STEMI on
the received electrocardiogram. Reduced-dose fibrinolytic
therapy would be initiated in the ambulance, coupled with
urgent transfer to a primary PCI center for immediate PCI.
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